Victorian Cancer Registry (Australia)

Database Contact Data

Professor Sue Evans
Director, Victorian Cancer Registry
200 Victoria Parade
East Melbourne VIC 3002
AUSTRALIA
Email: sue.evans@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61 (0) 3 9514 6751

Alternate Contact

Dr. Catherine Shang
Deputy Director, Victorian Cancer Registry
200 Victoria Parade
East Melbourne VIC 3002
AUSTRALIA
Email: catherine.shang@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61(0) 3 9514 6751

General Enquiries:
Email: vcr@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61(0) 3 9514 6751
Mail: 200 Victoria Parade, East Melbourne VIC 3002, AUSTRALIA

References of Studies Using/Describing Database

1. Bechelli ML, Ivanova K, Tan SS, Kumar B, Swiatek D, Arulananda S, Evans SM. ImpACT Project: Improving Access to Clinical Trials in Victoria, an Artificial Intelligence-Based Approach. JCO Clin Cancer Inform. 2025 Jan;9:e2400137.

2. Yang O, Zhang Y, To YH, M J IJzerman M, Liu J, Gibbs P, Trapani K, Pearson SA, Franchini F; PRIMCAT Group. Effects of clinical and socioeconomic factors on Medicare and patient costs for colorectal cancer in Australia: a retrospective multivariate regression analysis. BMJ Open. 2024 Dec 9;14(12):e081483.

3. de Boer J, Barnett R, Cardin A, Cimoli M, Davies L, Delany C, Dixon BJ, Evans SM, Findlay MW, Fox C, Ftanou M, Hart CD, Howard M, Iseli TA, Jackson A, Kranz S, Le BH, Lekgabe E, Lennox R, McLean LS, Neeson PJ, Ng SP, O'Reilly LA, Ramakrishnan A, Rowe D, Service C, Singh A, Thai AA, Tiong A, Yap T, Wiesenfeld D. Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach. Cancers (Basel). 2024 Mar 26;16(7):1277.

4. Afshar N, Dashti SG, Mar V, Te Marvelde L, Evans S, Milne RL, English DR. Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data. Int J Cancer. 2024 Mar 1;154(5):793-800.  

5. McPhail S, Barclay ME, Johnson SA, Swann R, Alvi R, Barisic A, Bucher O, Creighton N, Denny CA, Dewar RA, Donnelly DW, Dowden JJ, Downie L, Finn N, Gavin AT, Habbous S, Huws DW, May L, McClure CA, Møller B, Musto G, Nilssen Y, Saint-Jacques N, Sarker S, Shack L, Tian X, Thomas RJS, Thomson CS, Wang H, Woods RR, You H, Lyratzopoulos G; ICBP Module 9 Chemotherapy Group. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 2024 Mar;25(3):338-351.  

6. Gao L, Ugalde A, Livingston PM, White V, Watts JJ, Jongebloed H, McCaffrey N, Menzies D, Robinson S. Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis. BMC Health Serv Res. 2024 Feb 23;24(1):239.

7. Evans SM, Ivanova K, Cossio D, Pilgrim CHC, Croagh D, Zalcberg J, Giffard D, Golobic N, Di Muzio B, McLean C C, McLean K, Miller GC, Nicosia S, O'Rourke N, Parikh S, Standish R, Te Marvelde L. Registry-derived stage (RD-Stage) for capturing stage at diagnosis for pancreatic carcinoma in Australia. PLoS One. 2024 Jan 2;19(1):e0294443.

8. Pilgrim CHC, Finn N, Stuart E, Philip J, Steel S, Croagh D, Lee B, Tebbutt NC. Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit. ANZ J Surg. 2023 Nov;93(11):2638-2647.

9. Sung N, Muthusamy A, Finn N, Stuart E, Fox J, Yeo B. Surgical management of breast cancer in Victoria: A state-wide audit. Asia Pac J Clin Oncol. 2023 Aug;19(4):499-506.

10. Kang TMJ, Ratnayake G, Wada M, Phillips C, Ruben J, Senthi S, Foroudi F, Millar J, Ong WL. Real-world data on patterns and outcomes of radiation therapy for brain metastases in a population-based cohort of lung cancer patients in Victoria. J Med Imaging Radiat Oncol. 2023 Aug;67(5):546-555.

9/25/20: Finally we have our 325th profile...

The COTA database is sourced from electronic health records (EHR) of contributing academic, for-profit, and community oncologist provider sites and hospital systems. COTA contains detailed demographic, diagnostic, molecular and genomic testing, treatment, and outcome data. As of June 2020, COTA’s database is a geographically and genetically diverse set, comprised of rich longitudinal patient records collected from >40 unique locations across North America.

COTA (USA)

Database Contact Data

Email 1: info@cotahealthcare.com
Email 2: COTA Life Sciences <lifesciences@cotahealthcare.com>

Alternate Contact

If you cannot reach the database manager, please try completing the contact form at:
https://cotahealthcare.com/contact/

References of Studies Using/Describing Database

1. Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A. Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2024 Nov;65(11):1623-1633.

2. Spira A, Waters D, Ran T, Vadagam P, He J, Vanderpoel J, Donnelly A, Lin I. PP01. 68 Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy. Journal of Thoracic Oncology. 2024 Jul 1;19(7):e32.

3. Sinyavskaya L, Meche A, Faucher A, Hlavacek P, Johnson SMA, DiBonaventura M, Vekeman F, Ren J, Schepart A. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data. Curr Med Res Opin. 2024 May;40(5):789-801.

4. Sineshaw HM, Zettler CM, Prescott J, Garg M, Chakraborty S, Sarpong EM, Bai C, Belli AJ, Fernandes LL, Wang CK. Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy. Cancer Medicine. 2024 Apr;13(7):e7173.

5. Ip A, Mutebi A, Wang T, Jun M, Kalsekar A, Navarro FR, Wang A, Kamalakar R, Sacchi M, Elliott B. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis. Adv Ther. 2024 Mar;41(3):1226-1244.

6. Naomi Dempsey et al., A retrospective, descriptive analysis of a single-center experience with patients with metaplastic breast cancer. Journal of Clinical Oncology. 2024;42:16_suppl: e13173-e13173.

7. Shaji Kumar et al., Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2024;42:16_suppl: 7561-7561.

8. Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, Nador G, DiBonaventura MD. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncol. 2024;20(17):1175-1189.

9. Dhanda R, Wang CK, Belli AJ. Best Practices in the Curation and Use of Real-world Data in the Regulatory Pathway. Medicon Medical Sciences. 2023 Nov; 5(5): 38-40.

10. Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023 Apr 13:1-6.

Subscribe to